In September, US 10-year Treasury yields jumped from 4.79% to 5.17%, driven mainly by rising real interest rates rather than inflation expectations. This reflects confidence in the Federal Reserve's monetary policy and is fueled by a robust investment boom in the US, especially in the technology sector. In contrast, Europe shows limited investment growth, with Euro-area rates hitting capacity, which restricts further ECB tightening and makes European government bonds more attractive than US Treasuries. Investors are advised to maintain exposure to US growth stocks, selectively favor European exporters, and use currency hedges to optimize returns across regions.
The story about US and European economic dynamics is presented with Pluang market data for context. For readers following US stocks, here is Pluang's market snapshot as of Sep 27, 2026 17:11 WIB: out of 150 priced US stocks, 87 rose and 61 fell. Notable movers include BlackBerry Limited (USD 8.21, -5.96%), Roblox Corp (USD 46.44, -4.89%), and PayPal Holdings, Inc. (USD 55.04, +4.64%).
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Shurgard Self Storage, a leading European self-storage REIT, is currently trading at a significant discount to its net tangible assets (NTA) with a valuation of 0.48x NTA. It offers an attractive dividend yield of 4.5% and benefits from strong urbani...
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026. The event will be webcast live and available for replay on the ...
Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertami...
